Pruritus Therapeutics Market Growth Forecast 2025: Industry Trends, Market Size, and Projections

 The Business Research Company’s report on the Pruritus Therapeutics Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.

 
 How are market drivers shaping the future growth trajectory of the pruritus therapeutics industry?
 The rise in the incidence of dermatological disorders is expected to propel the growth of the pruritus therapeutics market going forward. Dermatological disorders refer to skin, hair, nail, and mucous membrane disorders ranging from acne and eczema to skin cancer and fungal infections. The underlying cause of itching often determines the use of pruritus treatments for dermatological illnesses. This condition uses topical treatments, emollients and moisturizers, immunosuppressant medications, and itching medications. For instance, in January 2024, according to the American Cancer Society, a US-based non-profit organization dedicated to eliminating cancer, there will be 108,270 reported cases of skin cancer, reflecting a 3.2% increase from the 104,930 cases reported in 2023. Therefore, the rise in the incidence of dermatological disorders is driving the growth of the pruritus therapeutics market.
 
 Access Your Free Sample of the Global Pruritus Therapeutics Market Report — Get Insights Now!
 https://www.thebusinessresearchcompany.com/sample.aspx?id=11907&type=smp
 
 What is the estimated market size of the pruritus therapeutics sector by 2029, based on current forecasts?
 The pruritus therapeutics market size has grown strongly in recent years. It will grow from $11.89 billion in 2024 to $12.51 billion in 2025 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to growth in the incidence of pruritus, diverse causes and conditions, rising aging population, and patient quality of life focus
 
 The pruritus therapeutics market size is expected to see strong growth in the next few years. It will grow to $16.05 billion in 2029 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to expanding knowledge of pruritus pathophysiology, innovative drug formulations, and delivery, focus on personalized medicine, rise in dermatological research and development, increasing awareness and diagnosis rates, and growing interest in botanical and herbal remedies. Major trends in the forecast period include the development of itch-specific receptor agonists and antagonists, market emphasis on personalized therapeutic approaches, integration of technology in itch monitoring and management, and collaborations for cross-disciplinary research.
 
 Gain Exclusive Market Insights — Customize Your Research Report Today For Fast Delivery!
 https://www.thebusinessresearchcompany.com/customise?id=11907&type=smp
 
 Who are the top players in the pruritus therapeutics market?
 Major companies operating in the pruritus therapeutics market include Pfizer Inc., Johnson & Johnson, AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, Eli Lilly and Company, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc. , Bausch Health Companies Inc., Galderma Laboratories LP, Cipla Limited, LEO Pharma AS, Cara Therapeutics Inc., GlaxoSmithKline Plc, Novan Inc., Escient Pharmaceuticals Inc., Nerre Therapeutic Ltd., EPI Health LLC, Trevi Therapeutics Inc., Evelo Biosciences, Toray Medical Co. Ltd.
 
 What are the major trends in the pruritus therapeutics market?
 Major companies operating in the pruritus therapeutics market are focused on developing targeted treatments for rare diseases and specific patient populations. such as non-systemic ileal bile acid transport inhibitor to provide personalized medicine that addresses unmet medical needs. A non-systemic ileal bile acid transport inhibitor is a type of medication that targets bile acid absorption in the intestine without significantly affecting the systemic circulation, thereby minimizing potential side effects. For instance, in June 2023, Ipsen, a France-based pharma company, received the Food and Drug Administration (FDA), a US-based federal agency of the Department of Health and Human Services, approval for Bylvay (odevixibat) for treating cholestatic pruritus in patients aged 12 months and older with Alagille syndrome (ALGS). Bylvay, a once-daily, non-systemic ileal bile acid transport inhibitor (IBATi), has minimal systemic exposure and is the first drug approved for cholestatic pruritus due to progressive familial intrahepatic cholestasis (PFIC) in the U.S. It was previously approved for PFIC treatment in Europe and is now available by prescription for eligible ALGS patients.
 
 Which geography holds the highest pruritus therapeutics market share?
 North America was the largest region in the pruritus treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pruritus therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
 
 Order Your Report Now For Swift Delivery
 https://www.thebusinessresearchcompany.com/report/pruritus-therapeutics-global-market-report
 
 How do different segments contribute to the overall expansion of the pruritus therapeutics market?
 The pruritus therapeutics market covered in this report is segmented –
 
 1) By Product: Corticosteroids, Antihistamines, Local Anesthetics, Counterirritants, Immunosuppressants, Calcineurin Inhibitors, Other Products
 2) By Route Of Administration: Oral, Parenteral, Topical
 3) By Disease Type: Atopic Dermatitis, Allergic Contact Dermatitis, Urticaria, Cutaneous T-Cell, Other Disease Types
 4) By End-User: Hospitals, Clinics, Other End Users
 
 Subsegments:
 1) By Corticosteroids: Topical Corticosteroids, Systemic Corticosteroids
 2) By Antihistamines: First-Generation Antihistamines, Second-Generation Antihistamines
 3) By Local Anesthetics: Topical Local Anesthetics
 4) By Counterirritants: Menthol-Based Products, Camphor-Based Products
 5) By Immunosuppressants: Topical Immunosuppressants, Systemic Immunosuppressants
 6) By Calcineurin Inhibitors: Tacrolimus Ointment, Pimecrolimus Cream
 7) By Other Products: Moisturizers And Emollients, Antipruritic Herbal Remedies, Combination Therapies
 
 Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
 https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11907
 
 How is the pruritus therapeutics market defined?
 Pruritus therapeutics refers to the treatments used to address an unpleasant skin sensation that causes an urge to scratch. This treatment is commonly used to stop swelling and inflammation in moderate-to-severe inflammatory skin diseases.
 
 About The Business Research Company:
 
 With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead. 
 
 Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
 
 Contact Us:
 
 The Business Research Company
 
 https://thebusinessresearchcompany.com/
 
 Europe: +44 207 1930 708
 
 Asia: +91 88972 63534
 
 Americas: +1 315 623 0293
 
 Email: info@tbrc.info
 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company